Literature DB >> 24735871

Gly25-Ser26 amyloid β-protein structural isomorphs produce distinct Aβ42 conformational dynamics and assembly characteristics.

Robin Roychaudhuri1, Aleksey Lomakin2, Summer Bernstein3, Xueyun Zheng3, Margaret M Condron1, George B Benedek2, Michael Bowers3, David B Teplow4.   

Abstract

One of the earliest events in amyloid β-protein (Aβ) self-association is nucleation of Aβ monomer folding through formation of a turn at Gly25-Lys28. We report here the effects of structural changes at the center of the turn, Gly25-Ser26, on Aβ42 conformational dynamics and assembly. We used "click peptide" chemistry to quasi-synchronously create Aβ42 from 26-O-acyliso-Aβ42 (iAβ42) through a pH jump from 3 to 7.4. We also synthesized Nα-acetyl-Ser26-iAβ42 (Ac-iAβ42), which cannot undergo O→N acyl chemistry, to study the behavior of this ester form of Aβ42 itself at neutral pH. Data from experiments monitoring increases in β-sheet formation (thioflavin T, CD), hydrodynamic radius (RH), scattering intensity (quasielastic light scattering spectroscopy), and extent of oligomerization (ion mobility spectroscopy-mass spectrometry) were quite consistent. A rank order of Ac-iAβ42>iAβ42>Aβ42 was observed. Photochemically cross-linked iAβ42 displayed an oligomer distribution with a prominent dimer band that was not present with Aβ42. These dimers also were observed selectively in iAβ42 in ion mobility spectrometry experiments. The distinct biophysical behaviors of iAβ42 and Aβ42 appear to be due to the conversion of iAβ42 into "pure" Aβ42 monomer, a nascent form of Aβ42 that does not comprise the variety of oligomeric and aggregated states present in pre-existent Aβ42. These results emphasize the importance of the Gly25-Ser26 dipeptide in organizing Aβ42 monomer structure and thus suggest that drugs altering the interactions of this dipeptide with neighboring side-chain atoms or with the peptide backbone could be useful in therapeutic strategies targeting formation of Aβ oligomers and higher-order assemblies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; amyloid β-protein; fibril formation; ion mobility spectroscopy–mass spectrometry; oligomerization

Mesh:

Substances:

Year:  2014        PMID: 24735871      PMCID: PMC4191920          DOI: 10.1016/j.jmb.2014.04.004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  41 in total

1.  The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain.

Authors:  Stefan F Lichtenthaler; Dirk Beher; Heike S Grimm; Rong Wang; Mark S Shearman; Colin L Masters; Konrad Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

3.  The 'O-acyl isopeptide method' for the synthesis of difficult sequence-containing peptides: application to the synthesis of Alzheimer's disease-related amyloid beta peptide (Abeta) 1-42.

Authors:  Youhei Sohma; Yoshio Hayashi; Maiko Kimura; Yousuke Chiyomori; Atsuhiko Taniguchi; Masato Sasaki; Tooru Kimura; Yoshiaki Kiso
Journal:  J Pept Sci       Date:  2005-07       Impact factor: 1.905

4.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

5.  Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages.

Authors:  Zhao Ren; Dale Schenk; Guriqbal S Basi; I Paul Shapiro
Journal:  J Biol Chem       Date:  2007-09-21       Impact factor: 5.157

6.  Structure of the 21-30 fragment of amyloid beta-protein.

Authors:  Andrij Baumketner; Summer L Bernstein; Thomas Wyttenbach; Noel D Lazo; David B Teplow; Michael T Bowers; Joan-Emma Shea
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

7.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.

Authors:  Summer L Bernstein; Nicholas F Dupuis; Noel D Lazo; Thomas Wyttenbach; Margaret M Condron; Gal Bitan; David B Teplow; Joan-Emma Shea; Brandon T Ruotolo; Carol V Robinson; Michael T Bowers
Journal:  Nat Chem       Date:  2009-07       Impact factor: 24.427

8.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  10 in total

1.  Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity.

Authors:  Robin Roychaudhuri; Xueyun Zheng; Aleksey Lomakin; Panchanan Maiti; Margaret M Condron; George B Benedek; Gal Bitan; Michael T Bowers; David B Teplow
Journal:  ACS Chem Neurosci       Date:  2015-10-19       Impact factor: 4.418

2.  Reducing synuclein accumulation improves neuronal survival after spinal cord injury.

Authors:  Stephanie M Fogerson; Alexandra J van Brummen; David J Busch; Scott R Allen; Robin Roychaudhuri; Susan M L Banks; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan; Jennifer R Morgan
Journal:  Exp Neurol       Date:  2016-02-13       Impact factor: 5.330

Review 3.  Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Authors:  Kirsten L Viola; William L Klein
Journal:  Acta Neuropathol       Date:  2015-01-22       Impact factor: 17.088

4.  Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure.

Authors:  Silvia Hilt; Ruiwu Liu; Izumi Maezawa; Tatu Rojalin; Hnin H Aung; Madhu Budamagunta; Ryan Slez; Qizhi Gong; Randy P Carney; John C Voss
Journal:  Front Chem       Date:  2022-05-26       Impact factor: 5.545

5.  Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.

Authors:  Xueyun Zheng; Deyu Liu; Robin Roychaudhuri; David B Teplow; Michael T Bowers
Journal:  ACS Chem Neurosci       Date:  2015-08-12       Impact factor: 4.418

6.  Amyloid β-protein assembly: The effect of molecular tweezers CLR01 and CLR03.

Authors:  Xueyun Zheng; Deyu Liu; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan; Michael T Bowers
Journal:  J Phys Chem B       Date:  2015-03-16       Impact factor: 2.991

Review 7.  Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.

Authors:  Hui Li; Xiaobing Wang; Hongmei Yu; Jing Zhu; Hongtao Jin; Aiping Wang; Zhaogang Yang
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  PI3K activation prevents Aβ42-induced synapse loss and favors insoluble amyloid deposit formation.

Authors:  Mercedes Arnés; Ninovska Romero; Sergio Casas-Tintó; Ángel Acebes; Alberto Ferrús
Journal:  Mol Biol Cell       Date:  2019-12-26       Impact factor: 4.138

9.  Single chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.

Authors:  Ying Zhang; Hai-Qiang Yang; Fang Fang; Lin-Lin Song; Yue-Ying Jiao; He Wang; Xiang-Lei Peng; Yan-Peng Zheng; Jun Wang; Jin-Sheng He; Tao Hung
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

10.  Aggregation Mechanism of Alzheimer's Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure.

Authors:  Anand Balupuri; Kwang-Eun Choi; Nam Sook Kang
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.